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 We studied extra-striatal PDE10A in early premanifest HD gene carriers 
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Abstract 
Huntington’s disease (HD) is a monogenic neurodegenerative disorder with an underlying pathology 
involving the toxic effect of mutant huntingtin protein primarily in striatal and cortical neurons. 
Phosphodiesterase 10A (PDE10A) regulates intracellular signalling cascades, thus having a key role 
in promoting neuronal survival. Using positron emission tomography (PET) with [
11
C]IMA107, we 
investigated the in-vivo extra-striatal expression of PDE10A in 12 early premanifest HD gene carriers. 
Image processing and kinetic modelling was performed using MIAKAT
TM
. Parametric images of 
[
11
C]IMA107 non-displaceable binding potential (BPND) were generated from the dynamic 
[
11
C]IMA107 scans using the simplified reference tissue model with the cerebellum as the reference 
tissue for nonspecific binding. We set a threshold criterion for meaningful quantification of 
[
11
C]IMA107 BPND at 0.30 in healthy control data; regions meeting this criterion were designated as 
regions-of-interest (ROIs).  MRI based volumetric analysis showed no atrophy in ROIs. We found 
significant differences in mean ROIs [
11
C]IMA107 BPND between HD gene carriers and healthy 
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controls. HD gene carriers had significant loss of PDE10A within the insular cortex and occipital 
fusiform gyrus compared to healthy controls. Insula and occipital fusiform gyrus are important brain 
areas for the regulation of cognitive and limbic function that is impaired in HD. Our findings suggest 
that dysregulation of PDE10A mediated intracellular signalling could be an early phenomenon in the 
course of HD with relevance also for extra-striatal brain areas. 
1. Introduction  
The intracellular enzyme phosphodiesterase 10A (PDE10A) is responsible for the hydrolysis of cyclic 
adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), and thus plays a 
role in regulating cyclic-nucleotide mediated intracellular signalling cascades serving a number of 
gene transcription factors and neurotransmitter receptors (1). PDE-10A has the potential to play a 
crucial role in mechanisms modulating motor, cognitive and neuropsychiatric functions associated 
with Huntington’s disease (HD). Recently, in vivo molecular imaging studies with PET have 
demonstrated 30-70% reduction of striatal PDE10A in HD gene carriers spanning from far onset 
premanifest (2) to near onset premanifest and early manifest (3) and advanced manifest (4) stages. 
Although PDE10A is mainly expressed in striatal medium spiny neurons, previous work in wild-type 
and HD animal models have reported PDE10A protein expression in extra-striatal brain areas (5-7). 
Evidence from human post-mortem data has shown PDE10A immunoreactivity is detectable at low 
concentrations in extra-striatal regions including cortical neurons (7, 8). Furthermore, in experimental 
studies PDE10A inhibition enhances cAMP response element-binding protein (CREB)-mediated 
signalling in cortical neurons of HD animal models indicating a direct effect of PDE10A on cortical 
neuronal survival (5, 9). Therefore, loss of extra-striatal PDE10A expression could be an important 
pathophysiological feature in the course of HD.   
In this study we assessed extra-striatal PDE10A expression in a group of normal controls using [
11
C] 
IMA107 PET, aiming to identify brain areas where [
11
C]IMA107 signal could be meaningfully 
quantified. Subsequently, we explored PDE10A expression, in those extra-striatal areas with 
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measurable signal, in a group of early premanifest HD gene carriers. We hypothesised that extra-
striatal areas that express quantifiable PDE10A levels in vivo could be altered early in HD. 
2. Methods 
2.1 Participants 
Twelve early, far onset premanifest HD gene carriers were identified from the HD gene carrier 
registry database of National Hospital of Neurology and Neurosurgery, Queen Square, London.  The 
time to symptom onset was estimated using a validated variant of the survival analysis formula, 
previously described (2).  All early premanifest HD gene carriers were clinically asymptomatic (Table 
1). Twelve healthy individuals matched for age and gender served as the control group. Full inclusion 
and exclusion criteria previously reported (2). Written informed consent was obtained from all study 
participants in accordance with the Declaration of Helsinki. The study was approved by the 
institutional review boards and the research ethics committee.  
Table 1: Clinical characteristics of early premanifest HD gene carriers and healthy controls  
 Healthy controls Premanifest HD gene carriers 
No 12 12 
Sex 9M/3F 7M/5F 
Age (years ± SD) 39.8 (±1.9) 41.2 (±7.5) 
CAG repeats (± SD) [range] - 41.8 (±1.3) [40-44] 
Disease Burden Score
1
  (± SD) 
[range] 
- 254.4 (±46.8) [153-323] 
90% probability to onset
2
 (years 
± SD) [range] 
- 25.0 (±6.9) [17-43] 
UHDRS TMS
3
 (± SD) 0 (±0) 0 (±0) 
UHDRS DCL
4
 (± SD) - 0 (±0) 
1
Disease burden score: age X (CAG length–35·5); 290% probability to onset = predicted years to Huntington’s 
disease symptoms onset (90% probability) calculated on the basis of variant of the survival analysis formula 
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described by (2); 
3
Unified Huntington Disease Rating Scale Total Motor Score (UHDRS TMS); 
4
Unified 
Huntington Disease Rating Scale Diagnostic Confidence Level (UHDRS DCL).  
2.2 Clinical assessments 
Motor function was assessed with the UHDRS TMS (10).  Functional capacity was assessed with 
clinician-based Total Functional Capacity scale (TFC), Independence Scale (IS), UHDRS functional 
assessment (10), and participant self-reported 36-Item Short Form Health Survey (SF-36) (11). 
Neuropsychiatric symptoms were evaluated with the shortened form of the problem behaviour 
assessment (PBA) (12), the Beck Depression Inventory-II (BDI-II) (13), and the Hamilton Depression 
Rating Scale (HDRS) (14). Cognitive assessments were carried out using the Cambridge 
Neuropsychological Test Automated Battery (CANTAB
®
). This incorporated assessments related to 
episodic memory (Paired Associate Learning), visual memory (Pattern Recognition Memory), 
attention (Reaction Time), executive function (One Touch Stockings of Cambridge) and language 
processing (Graded Naming Test).   
2.3 Scanning procedures 
PET and MR imaging was performed at Imanova Ltd, London, UK. Details of PET and MRI scanners 
have been described previously (2).  In brief, following an intravenous bolus mean dose of ±258 MBq 
[
11
C]IMA107, PET scans were obtained on a Biograph Hi-Rez 6 PET-CT scanner (Siemens) by 
acquiring dynamic emission data continuously for 90 minutes. All participants were scanned after 
withholding consumption of caffeinate beverages for 12 hours (15).  MRI scans included T1-weighted 
magnetization prepared rapid acquisition with gradient echo sequence (MPRAGE), for co-registration 
with PET images, acquired with a 32-channel head coil on a Siemens Magnetom Verio 3-T MRI 
scanner.  All sequences used a 1 mm
3
 voxel size, anteroposterior phase encoding direction, and a 
symmetric echo.  
2.4 Imaging data analysis 
Image processing and kinetic modelling was carried out using the Molecular Imaging and Kinetic 
Analysis Toolbox software package (MIAKAT
TM
: www.miakat.org; (16)), which also uses software 
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from SPM12 (Wellcome Trust Centre for Neuroimaging) and FSL (FMRIB, University of Oxford) 
and is implemented in MATLAB® (The Mathworks, Natick, MA, USA). The MIAKAT processing 
pipeline was followed, ensuring all quality control steps were completed to generate both parametric 
images and regional estimates of [
11
C]IMA107 BPND. 
Appropriate brain extraction fractional intensity threshold was selected and applied to the individual 
isotopic MRI, using the FSL Brain Extraction Tool (17). The T1-weighted MR image was segmented 
into white matter, grey matter and cerebrospinal fluid.  Normalisation of the T1 MR image into 
stereotaxic space enabled non-linear registration between template brain MRI [Montreal Neurological 
Institute (MNI)-152 template], stereotaxic neuroanatomical CIC atlas version 1.2 (18), and the 
individual subject. All images were checked following spatial normalization to ensure registration 
accuracy. Individual PET frames were corrected for head motion using frame-by-frame rigid 
registration using a frame with high signal-to-noise ratio as reference.  PET images were anatomically 
co-registered and to the corresponding MPRAGE MRI and subsequently spatially normalised into the 
T1-weighted MNI space.  
Parametric images of [
11
C]IMA107 non-displaceable binding potential (BPND) were generated from 
the dynamic [
11
C]IMA107 scans using a basis function implementation of the simplified reference 
tissue model (SRTM) (19), with the cerebellum as the reference tissue.  Previous PET studies have 
shown lower PDE10A uptake in the cerebellum (20) and a blocking study with selective PDE10A 
inhibitors has shown no changes in cerebellar [
11
C]IMA107 binding (Imanova internal data), 
confirming the suitability of the cerebellum as a reference region for the determination of the regional 
estimation of BPND.  
2.5 Region of interest analysis 
The anatomical CIC atlas version 1.2 (18) was used to define ROIs.  This atlas consists of a total of 
119 regions; cortical regions are modified from the Harvard-Oxford atlas, subcortical regions defined 
on the non-linear ICM152 template following MAN I guidelines and the thalamus replaced by 
thalamic connectivity atlas obtained from FMRIB, Oxford University (18, 20). Regional time-activity 
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data for ROIs was derived from dynamic PET data and regional BPND estimates obtained using the 
SRTM model with the cerebellum as the reference region. To ensure sufficient PDE10A expression a 
threshold of healthy control mean regional [
11
C]IMA107 BPND>0.30 was applied. Regions with 
average healthy control [
11
C]IMA107 BPND  ≤ 0.30 were excluded from statistical analysis.  
2.6 MRI volumetric analysis 
Since PDE10A is an intracellular enzyme, neuronal loss may affect its expression. We investigated 
volumetric changes in extra-striatal regions in our cohort of premanifest HD gene carriers compared 
to healthy controls. Volumetric ROIs were bilaterally defined on each subjects volumetric T1-
weighted MRI using the CIC v1.2 atlas. Volumes were extracted and corrected for total intracranial 
volume using validated methods (22). 
2.7 Statistical analysis  
Statistical analysis and graphical representations of data were performed with SPSS (SPSS version 
21.0, Chicago, Illinois, USA) and GraphPad Prism (version 6.0 c). For all variables, homogeneity and 
Gaussianity were tested with Bartlett and Kolmogorov-Smirnov tests. We investigated for possible 
outliers using the ROUT test in GraphPad Prism, with maximum desired false discovery rate (FDR) 
set to 1% (23). Any outliers were removed prior to further statistical analysis. Multivariate analysis of 
variance (MANOVA) was used to assess the overall effects of extra-striatal regional [
111
C]IMA107 
BPND between groups of premanifest HD gene carriers and healthy controls, reporting Pillai’s Trace P 
value. Independent parametric (t-test) and non-parametric (Mann-Whitney U) tests, followed by 
Bonferroni’s correction for multiple comparisons were used to assess effects of extra-striatal ROI 
[
11
C]IMA107 BPND between the two groups. We interrogated correlations between PET and clinical 
data, and between extra-striatal and striatal [
11
C]IMA107 BPND, using Spearman’s rs and applied the 
Benjamini-Hochberg correction to reduce the false discovery rate (24). The false discovery rate cut-
off was set at 0.05. For all comparisons the level α was set at P<0.05; all data presented as mean±SD. 
3. Results 
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3.1 Clinical measures 
No significant differences were found between early premanifest HD gene carriers and healthy 
controls in motor and functional (P>0.10), neuropsychiatric (P>0.10) and cognitive (P>0.10) 
assessments (previously reported (2)). 
3.2 MRI volumetric analysis  
Grey and white matter volumetric brain changes have been reported as one of the earliest changes in 
HD (25) with volumetric changes occurring in cortical regions (26, 27). Therefore it was important to 
identify if the cohort of premanifest HD gene carriers had significant volumetric changes, which could 
be a potential confounding factor when measuring intracellular PDE10A expression. MRI volumetric 
analysis confirmed there was no significant volume change in any extra-striatal regions between the 
groups of early premanifest HD gene carriers and healthy controls (P >0.10) (Supplementary Table 
S1).  
3.3 Extra-striatal PDE10A expression  
Extra-striatal brain regions meeting the threshold criteria in healthy controls, [
11
C]IMA107 
BPND>0.30, included insular cortex, occipital fusiform gyrus, occipital pole and posterior cingulate 
gyrus (Table 2, Figure 1a).  
We found significant differences in mean extra-striatal [
11
C]IMA107 BPND between the early 
premanifest HD gene carriers and healthy controls groups (P=0.013).  Early premanifest HD gene 
carriers had significantly decreased mean [
11
C]IMA107 BPND  in the insular cortex (P=0.029; -25.1%) 
(Figure 1b, Figure 2) and in the occipital fusiform gyrus (P=0.003; -41.9%) (Figure 1c) compared to 
the healthy controls. 
[
11
C]IMA107 BPND value for one healthy control subject in the occipital fusiform gyrus was identified 
as outliers and removed. Two early premanifest HD gene carriers displayed negative [
11
C]IMA107 
BPND values in the insular cortex, these values were removed from the HD gene carrier group in the 
insula only. Removal of these values did not affect the significance level.   
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Table 2: [
11
C]IMA107 BPND in anatomically defined regions comparing healthy controls and early 
premanifest HD gene carriers.    
Extra-striatal regions of 
interest  
Healthy 
Controls 
Premanifest 
HD gene 
carrier 
P value* % change 
in pHD 
Insular cortex 0.34 (±0.1) 0.26 (±0.1) 0.029 -25.1 
Occipital Fusiform gyrus 0.37 (±0.1) 0.21 (±0.1) 0.003 -41.9 
Occipital Pole 0.35 (±0.1) 0.34 (±0.1) >0.10 -2.7 
Posterior Cingulate gyrus 0.38 (±0.2) 0.32 (±0.1) >0.10 -17.6 
Selected regions with control [
11
C]IMA107 BPND>0.30. *P values are Bonferroni corrected. Negative 
percentage change indicates lower PDE10A expression in premanifest HD gene carriers compared to controls.   
Figure 1: Loss of PDE10A expression in the insular cortex and occipital fusiform gyrus in early 
premanifest HD gene carriers 
 
(a)Column bar graph showing mean [
11
C]IMA107 BPND extra-striatal regions with control BPND >0.30 for 
healthy controls (HC) and premanifest HD gene carriers (pHD). Bonferroni corrected *P<0.05, **P<0.01. 
Scatterplots showing distribution of individual BPND values in the insular cortex (b) and the occipital fusiform 
gyrus (c). Error bars represent mean ± standard deviation (SD).  
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Figure 2: Significant loss of PDE10A within the insular cortex in premanifest HD gene carriers 
compared to healthy controls 
 
Sagittal summed [
11
C]IMA107 PET images co-registered and fused with 3-T MRI images for the insula of a 40 
year old female showing normal insula [
11
C]IMA107 binding (BPND = 0.451) (left); a 43 year old male 
premanifest HD gene carrier (CAGr: 43; DBS: 322.5; 17 years from predicted onset) showing moderate 
decreased insula [
11
C]IMA107 binding (BPND = 0.215) (middle); a 44 year old male premanifest HD gene 
carrier (CAGr: 41; DBS: 236.5; 27 years from predicted onset) showing severe decreased insula [
11
C]IMA107 
binding (BPND = 0.173) (right). Colour bar reflects range of [
11
C]IMA107 BPND intensity.  
 
We investigated possible association between PDE10A expression and clinical measures, however no 
significant correlation between [
11
C]IMA107 BPND and clinical data were identified in any regions.   
To confirm the [
11
C]IMA107 signal detected in the insula and occipital fusiform gyrus specifically 
measured PDE10A enzyme, and not just background noise, we looked for correlations with 
[
11
C]IMA107 signal in striatal regions where PDE10A is known to be highly expressed (2).  We 
found significant positive correlations between loss of [
11
C]IMA107 BPND in the insula with loss of 
[
11
C]IMA107 BPND in the striatum (rs = 0.733; P<0.001), caudate (rs = 0.711; P <0.001), globus 
pallidus (rs = 0.573; P = 0.006) and putamen (rs = 0.726; P <0.001) (Figure 3A); signal loss in the 
occipital fusiform gyrus also significantly correlated with signal loss in the striatum (rs = 0.575; P = 
0.010), caudate (rs = 0.534; P = 0.015), globus pallidus (rs = 0.428; P = 0.042) and putamen (rs = 
0.608; P = 0.010) (Figure 3B).   
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Figure 3 Correlation between [
11
C]IMA107 BPND in anatomically defined extra-striatal and striatal 
regions of interest 
 
Loss [
11
C]IMA107 BPND in (A) the insular cortex correlated with loss of [
11
C]IMA107 BPND  in the striatum (rs  
= 0.733; P < 0.001), caudate ( rs  = 0.711; P < 0.001), globus pallidus (rs  = 0.573; P = 0.006) and putamen ( rs 
= 0.726; P < 0.001); (B) the occipital fusiform gyrus correlated with loss of [
11
C]IMA107 BPND in the striatum 
(rs = 0.575; P = 0.010), caudate (rs = 0.534; P = 0.015), globus pallidus ( rs = 0.428; P = 0.042) and putamen (rs 
= 0.608; P = 0.010). 
 
4. Discussion  
Using non-invasive imaging, we demonstrated significant loss of extra-striatal PDE10A expression, 
specifically 25% loss in the insular cortex and 42% loss in the occipital fusiform gyrus, in early 
premanifest HD gene carriers who were several years before their predicted symptomatic onset.  We 
did not detect significant volume change in our HD gene carriers, indicating that [
11
C]IMA107 BPND 
loss reported here is not due to regional atrophy. Previous work has shown the importance of PDE10A 
in the pathophysiology of HD, in particular the loss of striatal PDE10A in premanifest and manifest 
stages of HD (2-4).  The current study demonstrates altered PDE10A expression beyond the basal 
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ganglia, early in the course of the disease, and supports PDE10A as potentially one of the earliest 
pathophysiological features of HD.    
The insula and occipital fusiform gyrus are key regions associated with the development of cognitive 
and limbic functions (27-30). Imaging studies have previously demonstrated changes in the insula, 
occipital and fusiform cortex in premanifest and symptomatic HD. PET studies have reported 
increased microglial activation (31, 32) and loss of D2/D3 dopamine receptor availability (33) in the 
insular cortex of premanifest and manifest HD gene carriers. PET with [
18
F]flurodeoxyglucose 
showed loss of metabolic activity in the insula while the occipital cortex showed increased metabolic 
activity in early premanifest HD gene carriers (34).  fMRI studies report reduced neural activity in the 
insula of early premanifest HD (35), and reduced neuronal activity within the fusiform cortex (28) and 
occipital cortex (36) in early manifest HD. Results from the present study suggest dysregulation of 
PDE10A also occurs in the insula and occipital fusiform gyrus; however the relationship between 
these pathophysiological events is currently unknown.   
PDE10A has a key role in regulating intracellular signalling and given the functional significance of 
the insula and occipital fusiform gyrus, loss of PDE10A expression reported here could be an early 
phenomenon underlying subsequent development of cognitive and behavioural symptoms in the 
course of HD. In our study we did not find associations between loss of PDE10A expression in the 
insula or occipital fusiform gyrus and cognitive and behavioural performance as measured by 
specialised tools. However, our sample size was relatively small and premanifest HD gene carriers at 
a far onset stage with intact brain functions. Our design is limited due to the cross-sectional nature; 
however, it could be possible that future prospective studies may show that loss of PDE10A 
expression in the insula and occipital fusiform gyrus are associated with the risk of developing 
cognitive and behavioural issues in manifest HD. Furthermore, in HD the affected extra-striatal 
regions could play a role in visuomotor (37), visuospatial (38) and oculomotor (39, 40), as well as 
facial expression deficits (41, 42). In the present study we did not examine visual function or face 
recognition. Therefore, further studies with specific clinical measures assessing such deficits may 
highlight clinical associations.  
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To support the reliability of our data, we demonstrated that loss of [
11
C]IMA107 signal in the insula 
and occipital fusiform gyrus correlated with loss of [
11
C]IMA107 signal in striatal regions; striatal loss 
of PDE10A signal has been previously reported (2).  Further work is needed to fully validate the use 
of the cerebellum as a reference region for quantification of low [
11
C]IMA107 signal detected in 
extra-striatal regions and estimate the level of specific compared to nonspecific binding. Moreover, 
alternative higher affinity ligands such as [
11
C]IMA106 (20) may facilitate the imaging extra-striatal 
regions, further confirming the reliability of extra-striatal BPND values presented here.  
A recent one year follow-up study demonstrated a mean annual loss of PDE10A of 16.6% in the 
caudate, 6.9% in the putamen and 5.8% in the globus pallidus (43).  Furthermore, two genetic studies 
have identified PDE10A mutations as a cause of hyperkinetic movement disorders (44, 45) 
confirming the role of PDE10A in regulating striato-cortical activity and supporting an important role 
of PDE10A in the pathophysiology of HD. Findings that PDE10A changes can be detected outside the 
striatum, even at early premanifest stages, further increases the value of PDE01A as a biomarker to 
track disease progression in HD. 
In conclusion, we provide in vivo evidence for the loss of PDE10A expression in insula and occipital 
fusiform gyrus a number of years before symptomatic onset in premanifest HD gene carriers. Further 
studies are needed to explore the relevance of extra-striatal PDE10A loss in the development of 
cognitive and behavioural symptoms. This study supports the increasing evidence for the role of PDEs 
in neurodegenerative disorders and the use of [
11
C]IMA107 PET as a robust imaging tool to study 
PDE10A in vivo in the human brain and disease.  
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